ORTHOCELL LIMITED — Board/Management Information 2023

Dec 21, 2023

==> picture [594 x 104] intentionally omitted <==

Orthocell Board Change

• Orthocell founding Board member and former Chairman, Dr Stewart Washer, retires from the Orthocell Board.

• With an experienced senior, multinational advisory team and an advanced regenerative medicine portfolio, Orthocell is ideally positioned to drive its products into the global markets

Perth, Australia; 22 December 2023: Regenerative medicine company Orthocell Limited (ASX: OCC, “Orthocell” or the “Company”) today announced that founding Board member and former Chairman, Dr Stewart Washer, has retired from the Company’s Board.

Dr Washer has completed the transition from his previous role as the long-standing Chair and has fully handed over the reins to new Chairman John Van Der Wielen. Stewart made the decision to retire from the Orthocell Board after having served almost 10 years to allow him to pursue other interests.

Orthocell Chairman, Mr John Van Der Wielen, said: “Stewart’s commitment to the success of Orthocell in the early phase of the company was commendable and I am so appreciative of his assistance in my early days as incoming Chair of the Orthocell Board. I sincerely wish Stewart all the best in his future endeavours.”

Orthocell Board now has five Directors comprising four Non-Executive Directors and one Executive Director. The recent appointment of Professor Fiona Wood, independent non-executive Director Dr Ravi Thadhani and Chairman Mr John Van Der Wielen to the Orthocell Board, has strengthened the leadership team as the Company prepares for the next phase of development and commercialisation of its unique medical devices and cellular therapies.

Orthocell CEO Paul Anderson stated that Dr Washer was pivotal to the successful IPO of Orthocell back in 2014 and his contribution to Orthocell’s transition from early phase R&D company to a commercial success is greatly appreciated.

Release authorised by:

Paul Anderson Managing Director, Orthocell Ltd

For more information, please contact:

General & Investor enquiries

Media enquiries

Paul Anderson Haley Chartres Orthocell Limited H^CK Director Managing Director P: +61 8 9360 2888 P: +61 423 139 163 E: paulanderson@orthocell.com.au E: haley@hck.digital

==> picture [594 x 104] intentionally omitted <==

About Orthocell Limited

ACN 118 879 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell’s portfolio of products include CelGro™ platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in US FDA (510k), Australia (ARTG) and Europe (CE Mark) and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently received approval and reimbursement in Australia and is distributed exclusively by Device Technologies in the Australian market. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company’s other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer, manufacturing scale up and FDA engagement in advance of a randomised controlled study under FDA supervision.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @Orthocellltd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate, ”expect,” “intend,” “may,” “plan,” “predict,” “project,” “target, ”potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for is product candidates. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.